Dbv Technologies

Dbv Technologies company information, Employees & Contact Information

Explore related pages

Related company profiles:

DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively. We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need. This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin. Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy. Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.

Company Details

Employees
188
Address
107, Avenue De La République, Châtillon,france 92320,france
Phone
+33 (0)1 55 42 78 78
Email
ge****@****ies.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Châtillon, France
Looking for a particular Dbv Technologies employee's phone or email?

Dbv Technologies Questions

News

DBV Technologies Announces Sale of approximately $30 - GlobeNewswire

DBV Technologies Announces Sale of approximately $30 GlobeNewswire

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting - Yahoo Finance

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Yahoo Finance

Clinical-Stage Biotech DBV Technologies Featured at H.C. Wainwright Global Investment Conference - Stock Titan

Clinical-Stage Biotech DBV Technologies Featured at H.C. Wainwright Global Investment Conference Stock Titan

DBV Technologies Announces Resignation of Board Member - GlobeNewswire

DBV Technologies Announces Resignation of Board Member GlobeNewswire

$30M ADS Sale: DBV Technologies Issues 2,307,692 ADSs via ATM Program on Nasdaq and Euronext Paris - Stock Titan

$30M ADS Sale: DBV Technologies Issues 2,307,692 ADSs via ATM Program on Nasdaq and Euronext Paris Stock Titan

DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old - Yahoo Finance

DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old Yahoo Finance

Biotech Board Shake-up: DBV Technologies Director Exits Amid VIASKIN Peanut Patch Development - Stock Titan

Biotech Board Shake-up: DBV Technologies Director Exits Amid VIASKIN Peanut Patch Development Stock Titan

DBV Technologies’ stock slides as financial woes worsens - Pharmaceutical Technology

DBV Technologies’ stock slides as financial woes worsens Pharmaceutical Technology

$150 Million Financing: DBV Technologies Launches New ATM Program to Fund VIASKIN Peanut Patch Development - Stock Titan

$150 Million Financing: DBV Technologies Launches New ATM Program to Fund VIASKIN Peanut Patch Development Stock Titan

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial - Yahoo Finance

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial Yahoo Finance

DBV Technologies Announces Financing of up to $306.9 - GlobeNewswire

DBV Technologies Announces Financing of up to $306.9 GlobeNewswire

DBV Technologies Liquidity Contract Update: Over €3M in Trading Volume Reveals Market Activity - Stock Titan

DBV Technologies Liquidity Contract Update: Over €3M in Trading Volume Reveals Market Activity Stock Titan

DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer - GlobeNewswire

DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer GlobeNewswire

DBV Technologies Secures Agreement with FDA on Safety - GlobeNewswire

DBV Technologies Secures Agreement with FDA on Safety GlobeNewswire

DBV Confirms Alignment with U.S. FDA on Accelerated - GlobeNewswire

DBV Confirms Alignment with U.S. FDA on Accelerated GlobeNewswire

Q&A: DBV Technologies announces progress on Viaskin Peanut patch - Healio

Q&A: DBV Technologies announces progress on Viaskin Peanut patch Healio

DBV Technologies Begins Pivotal Peanut Allergy Study, Aims for 2026 FDA Submission. - Yahoo Finance

DBV Technologies Begins Pivotal Peanut Allergy Study, Aims for 2026 FDA Submission. Yahoo Finance

DBV Technologies to Participate in Upcoming EAACI 2024 Congress - Yahoo Finance

DBV Technologies to Participate in Upcoming EAACI 2024 Congress Yahoo Finance

Why DBV Technologies S.A. (DBVT) is Surging in 2025 - Yahoo Finance

Why DBV Technologies S.A. (DBVT) is Surging in 2025 Yahoo Finance

Patch effective through 36 months in treating toddlers with peanut allergy - Healio

Patch effective through 36 months in treating toddlers with peanut allergy Healio

New data: Viaskin Peanut patch improves treatment benefit through 36 months - Contemporary Pediatrics

New data: Viaskin Peanut patch improves treatment benefit through 36 months Contemporary Pediatrics

Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study) - ScienceDirect.com

Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study) ScienceDirect.com

DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe - GlobeNewswire

DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe GlobeNewswire

DBV Technologies raises $30 million through ADS sale on Nasdaq - Investing.com

DBV Technologies raises $30 million through ADS sale on Nasdaq Investing.com

DBV Technologies: A Great Time To Sell (NASDAQ:DBVT) - Seeking Alpha

DBV Technologies: A Great Time To Sell (NASDAQ:DBVT) Seeking Alpha

With 45% ownership in DBV Technologies S.A. (EPA:DBV), institutional investors have a lot riding on the business - simplywall.st

With 45% ownership in DBV Technologies S.A. (EPA:DBV), institutional investors have a lot riding on the business simplywall.st

DBV Technologies Announces Private Placement Financing of $194 Million - GlobeNewswire

DBV Technologies Announces Private Placement Financing of $194 Million GlobeNewswire

FDA Wants More Data on Viaskin Peanut Allergy Patch - Medical Professionals Reference

FDA Wants More Data on Viaskin Peanut Allergy Patch Medical Professionals Reference

Epicutaneous immunotherapy: A review of safety and efficacy - Anagnostou - 2025 - Pediatric Allergy and Immunology - Wiley Online Library

Epicutaneous immunotherapy: A review of safety and efficacy - Anagnostou - 2025 - Pediatric Allergy and Immunology Wiley Online Library

DBV Technologies Reports Progress in Clinical Trials and Financing - TipRanks

DBV Technologies Reports Progress in Clinical Trials and Financing TipRanks

Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025 - GlobeNewswire

Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025 GlobeNewswire

DBV Technologies Announces Board Member Resignation - TipRanks

DBV Technologies Announces Board Member Resignation TipRanks

FDA turns back DBV Technologies' peanut allergy patch, raising questions about its design - Fierce Biotech

FDA turns back DBV Technologies' peanut allergy patch, raising questions about its design Fierce Biotech

FDA Issues CRL for DBV Technologies’ Viaskin Peanut Allergy Patch - BioSpace

FDA Issues CRL for DBV Technologies’ Viaskin Peanut Allergy Patch BioSpace

Long-Term Data Support Benefits of Viaskin Peanut Patch - Medical Professionals Reference

Long-Term Data Support Benefits of Viaskin Peanut Patch Medical Professionals Reference

DBV’s Viaskin Peanut: still viable despite phase III failure - Pharmaceutical Technology

DBV’s Viaskin Peanut: still viable despite phase III failure Pharmaceutical Technology

Peanut allergy market set for remarkable growth to 2027 - Pharmaceutical Technology

Peanut allergy market set for remarkable growth to 2027 Pharmaceutical Technology

Baker Bros. Advisors Buys More DBV Technologies S.A. (DBVT); Visium Asset Management Goes Long On Pacira Pharmaceuticals Inc. (PCRX) - Insider Monkey

Baker Bros. Advisors Buys More DBV Technologies S.A. (DBVT); Visium Asset Management Goes Long On Pacira Pharmaceuticals Inc. (PCRX) Insider Monkey

Top Dbv Technologies Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant